ArticleEuropean radiology2014
Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound.
Article in European radiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06305312 (Community Services Navigation to Advance Health Equity in Breast Cancer Screening), which is not on this map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Quantifying the impact of treatment delays on breast cancer survival outcomes: a comprehensive meta-analysis.GeroScience · 2026Pooled it
- Has tumor doubling time in breast cancer changed over the past 80 years? A systematic review.Cancer medicine · 2021Pooled it
- Combined diagnosis of multiparametric MRI-based deep learning models facilitates differentiating triple-negative breast cancer from fibroadenoma magnetic resonance BI-RADS 4 lesions.Journal of cancer research and clinical oncology · 2023Trial
- Machine learning-based prediction of breast cancer growth rate in vivo.British journal of cancer · 2019Trial
- Estimating the carcinogenesis timelines in early-onset versus late-onset cancers and changes across birth cohorts.Science advances · 2026Article
- Time-Varying Hormonal Treatment and Metastasis-Free Survival Among ER+ Breast Cancer Patients: A Natural History Modelling Approach.Statistics in medicine · 2026Article
- An Extracellular Matrix-Producing Subset of Cancer-Associated Fibroblasts Drives Chemoresistance in Breast Cancer via SRC Activation and G0S2 Upregulation.Cancer research · 2026Article
- Modeling Early-Onset Cancer Kinetics Reveals Changes in Underlying Risk and the Impact of Population Screening.Cancer research · 2025Article
- Predicting short- to long-term breast cancer risk from longitudinal mammographic screening history.NPJ breast cancer · 2025Article
- Tumour growth rate and invasive interval cancer characteristics in a UK breast cancer screening population.European radiology · 2025Article
- Spatiotemporal dynamics of tumor-CAR T-cell interaction following local administration in solid cancers.PLoS computational biology · 2025Article
- Modeling early-onset cancer kinetics to study changes in underlying risk, detection, and impact of population screening.medRxiv : the preprint server for health sciences · 2025Article
- Prolonged time to breast cancer surgery and the risk of metastasis: an explorative simulation analysis using epidemiological data from Germany and the USA.Breast cancer research and treatment · 2025Article
- Article
- Predicting Tumor Volume Doubling Time and Progression-Free Survival in Untreated Patients from Patient-Derived-Xenograft (PDX) Models: A Translational Model-Based Approach.The AAPS journal · 2024Article
- Minimum latency effects for cancer associated with exposures to radiation or other carcinogens.British journal of cancer · 2024Article
- Risk of metastasis in breast cancer through delay in start of primary therapy.The Lancet regional health. Europe · 2023Article
- Long-Term Performance of an Image-Based Short-Term Risk Model for Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Impact of the COVID-19 Pandemic on Melanoma Diagnosis: Increased Breslow Thickness in Primary Melanomas-A Single Center Experience.International journal of environmental research and public health · 2022Article
- Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe aim of our study was to evaluate the tumour volume doubling time (TVDT) of molecular breast cancer subtypes by serial ultrasound (US).
methodsSixty-six patients (mean age, 50 years; range, 29-78 years) with invasive breast cancer underwent initial and follow-up breast US examinations (at least three months apart) with no intervention. TVDT was determined using the tumours' greatest dimensions in two orthogonal planes. The results were compared with clinical, imaging, and tumour variables and molecular subtypes (oestrogen receptor [ER]-positive, human epidermal growth factor receptor 2 [HER2]-positive, and triple negative) using a multiple linear regression analysis.
resultsTVDT exhibited a wide range (46-825 days; median, 141 days) with an overall mean of 193 ± 141 days and mean values of 241 ± 166 days for ER-positive tumours (n = 37), 162 ± 60 days for HER2-positive tumours (n = 12), and 103 ± 43 days for triple-negative tumours (n = 17) (P < 0.0001). In a multivariate regression analysis, compared to other features, only the different molecular breast cancer subtypes showed significant difference in TVDT (P < 0.0001).
conclusionsTVDT differed significantly among the three molecular breast cancer subtypes, with the triple-negative tumours showing the fastest growth. KEY POINTS: Knowledge of tumour volume doubling time provides clues for improving screening. TVDT assessed by serial US differed significantly between breast cancer subtypes. Triple-negative tumours had 2.4-fold shorter TVDT compared to ER-positive tumours. Tumours classified as BI-RADS 3 had shorter TVDT than BI-RADS 4.
Indexed as
Identifiers
24895040What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.